Müller, Sven
Weyhe, Dirk
Herrle, Florian
Horvath, Philipp
Bachmann, Robert
von Ehrlich-Treuenstätt, Viktor
Heger, Patrick
Nasir, Nadir
Klose, Christina
Ritz, Alexander
Sander, Anja
Grohmann, Erich
Dörr-Harim, Colette
Mihaljevic, André L. https://orcid.org/0000-0003-1902-657X
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KG2023)
Universitätsklinikum Ulm
Article History
Received: 11 November 2022
Accepted: 10 January 2023
First Online: 1 February 2023
Declarations
:
: According to § 15 of the Professional Code for Physicians in Germany (Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte), the coordinating investigator has consulted the Ethics Committee (EC) of the University of Ulm before the start of the trial. Approval was granted on 23 May 2022 (Number 76/22). Also, all other participating sites will or have already consulted their responsible ethics committees, before recruitment is started at the respective site. Any changes have to be documented in a written amendment. They will be restricted to exceptional cases. Amendments then become part of the clinical trial protocol. The EC will be informed of all subsequent protocol amendments in order to determine whether formal approval must be sought and whether the informed consent document should also be revised. The EC will be informed of the end of the trial by the coordinating investigator.
: A model consent form is provided on request.
: The authors declare that they have no competing interests.